Browse

Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer

Cited 374 time in Web of Science Cited 404 time in Scopus
Authors
Lee, Keun Seok; Chung, Hyun Cheol; Im, Seock Ah; Park, Yeon Hee; Kim, Chul Soo; Kim, Sung-Bae; Rha, Sun Young; Lee, Min Young; Ro, Jungsil
Issue Date
2007-05-04
Publisher
Springer Verlag
Citation
Breast Cancer Res Treat. 2008 Mar;108(2):241-50. Epub 2007 May 3.
Keywords
AdultAgedAntineoplastic Agents, Phytogenic/administration & dosage/adverseeffects/chemistry/*therapeutic useBreast Neoplasms/*drug therapy/mortality/pathologyChemistry, PharmaceuticalDrug Administration Schedule*Drug CarriersDrug CompoundingFemaleHumansInfusions, IntravenousKaplan-Meiers EstimateKorea*MicellesMiddle AgedNeoplasm MetastasisPaclitaxel/administration & dosage/adverse effects/chemistry/*therapeuticusePolyethylene Glycols/chemistryPolymers/*chemistryTime FactorsTreatment Outcome
Abstract
Genexol-PM is a novel Cremophor EL-free polymeric micelle formulation of paclitaxel. This single arm, multicenter phase II study was designed to evaluate the efficacy and safety of Genexol-PM in patients with histologically confirmed metastatic breast cancer (MBC). Forty-one women received Genexol-PM by intravenous infusion at 300 mg/m2 over 3 h every 3 weeks without premedication until disease progression or intolerability. A total of 331 chemotherapy cycles were administered, with a median of 8 cycles per patient (range, 1-16). Overall response rate was 58.5% (95% CI: 43.5-72.3) with 5 complete responses and 19 partial responses. Thirty-seven patients who received Genexol-PM as a first-line therapy for their metastatic disease showed a response rate of 59.5% (95% CI: 43.5-73.7), and two responses were reported in four patients treated in the second-line setting for their metastatic disease. The median time to progression (TTP) for all patients was 9.0 months (range, 1.0-17.0+ months). Grade 3 non-hematologic toxicities included sensory peripheral neuropathy (51.2%), and myalgia (2.4%). Eight patients (19.5%) experienced hypersensitivity reactions, with grade 3 in two patients. Hematologic toxicities were grade 3 and 4 neutropenia (51.2 and 17.1%, respectively), and grade 1 and 2 thrombocytopenia (22.0%). Notably, no febrile neutropenia was observed. Genexol-PM appears a promising new paclitaxel in view of significant efficacies. Further trials with different dosing schedules, durations of delivery, or in combination with other drugs are warranted.
ISSN
0167-6806 (Print)
Language
English
URI
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17476588

https://hdl.handle.net/10371/23795
DOI
https://doi.org/10.1007/s10549-007-9591-y
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse